Inoue K, Nishimura H, Kubota J, Kawamura K
Third Department of Internal Medicine, Osaka Medical College, Takatsuki City, Osaka, Japan.
Hypertension. 1999 Sep;34(3):525-30. doi: 10.1161/01.hyp.34.3.525.
Contrary to previous reports, recent enzymatic assays showed the predominance of chymase-like activity in rat arteries. We determined the existence and significance of such alternative pathways in rat carotid arteries by measuring contraction of arterial rings in organ baths and blood pressure in conscious rats. Hamster aorta served as a positive control for chymase. Temocapril (30 micromol/L) inhibited the contractions to angiotensin (Ang) I (10(-9) to 10(-5) mol/L) except at high concentrations of Ang I (>10(-7) mol/L). Addition of chymostatin (100 micromol/L) to temocapril exerted a synergistic inhibitory effect. Hamster aorta gave similar results, except that temocapril was 30-fold less effective than in rat arteries. [Pro(11), D-Ala(12)]Ang I (10(-8) to 10(-5) mol/L), a chymase-specific substrate, provoked similar responses in rat and hamster arteries; chymostatin, but not temocapril, attenuated the responses. CV 11974 (30 micromol/L), an Ang II type 1 receptor antagonist, abolished the responses to both peptides. In conscious rats, Ang I (0.03 to 30 microg/kg) and [Pro(11),D-Ala(12)]Ang I (7 to 700 microg/kg) produced similar pressor responses. Not only CV 11974 (1 mg/kg) but also temocapril (2 mg/kg) abolished Ang I-induced responses in vivo. CV 11974, but not temocapril, inhibited responses to [Pro(11), D-Ala(12)]Ang I. Our results showed the presence of the alternative pathway in rat arteries, but it did not play a major role. Arteries with the opposing characteristics of chymase responded equally to [Pro(11),D-Ala(12)]Ang I. These findings suggest that biochemical and [Pro(11),D-Ala(12)]Ang I-derived results may not reflect the functional significance of chymase.
与先前的报道相反,最近的酶活性测定表明,大鼠动脉中类糜酶活性占主导地位。我们通过测量器官浴中动脉环的收缩和清醒大鼠的血压,来确定大鼠颈动脉中这种替代途径的存在及其意义。仓鼠主动脉用作糜酶的阳性对照。替莫卡普利(30微摩尔/升)可抑制对血管紧张素(Ang)I(10^(-9)至10^(-5)摩尔/升)的收缩反应,但高浓度Ang I(>10^(-7)摩尔/升)除外。在替莫卡普利中加入抑肽酶(100微摩尔/升)可产生协同抑制作用。仓鼠主动脉给出了类似的结果,只是替莫卡普利的效力比在大鼠动脉中低30倍。[脯氨酸(11),D-丙氨酸(12)]Ang I(10^(-8)至10^(-5)摩尔/升),一种糜酶特异性底物,在大鼠和仓鼠动脉中引发类似反应;抑肽酶而非替莫卡普利可减弱这些反应。CV 11974(30微摩尔/升),一种血管紧张素II 1型受体拮抗剂,可消除对两种肽的反应。在清醒大鼠中,Ang I(0.03至30微克/千克)和[脯氨酸(11),D-丙氨酸(12)]Ang I(7至700微克/千克)产生类似的升压反应。不仅CV 11974(1毫克/千克),而且替莫卡普利(2毫克/千克)均可在体内消除Ang I诱导的反应。CV 11974而非替莫卡普利可抑制对[脯氨酸(11),D-丙氨酸(12)]Ang I的反应。我们的结果表明大鼠动脉中存在替代途径,但它并不起主要作用。具有相反糜酶特性的动脉对[脯氨酸(11),D-丙氨酸(12)]Ang I的反应相同。这些发现表明,生化和[脯氨酸(11),D-丙氨酸(12)]Ang I衍生的结果可能无法反映糜酶的功能意义。